Percutaneous coronary intervention utilizing a new endothelial progenitor cells antibody-coated stent: A prospective single-center registry in high-risk patients
Percutaneous coronary intervention utilizing a new endothelial progenitor cells antibody-coated stent: A prospective single-center registry in high-risk patients
复制标题
DOI：
10.1002/ccd.21437
复制
发表时间：
2008-04-01
影响因子：
2.3
通讯作者：
Di Sciascio, Germano
中科院分区：
文献类型：
--
作者：
Miglionico, Marco;Patti, Giuseppe;Di Sciascio, Germano
目的：前瞻性评估循环内皮祖细胞（EPC）捕获支架植入术在具有高危血管造影和/或临床特征的连续患者队列中的效果。背景：原生r -支架（TM）是一种不锈钢冠状动脉支架，覆盖有EPC表面抗原特异性抗体，旨在促进设备上融合功能内皮层的形成；可以想象，这可以防止支架血栓形成和再狭窄。方法：2005年11月至2007年3月，80例患者在罗马大学生物医学院接受了93例EPC捕获支架。患者具有以下两种或两种以上的高危特征：糖尿病（33%），不稳定冠状动脉综合征（73%），左心室功能障碍（8%），多血管介入（9%），B2/C病变（56%）。结果：79/80例（98%）患者获得急性成功，无q波心肌梗死（MI）、院内死亡或紧急搭桥手术；无患者发生急性或亚急性支架血栓形成。78例患者随访（平均14 +/- 4个月）：1例患者发生非心源性死亡，1例患者发生急性心肌梗死；没有病人需要搭桥手术；10例（13%）行经皮靶区血管重建术（TLR）；3名患者（4%）对非靶血管进行了再干预。Kaplan-Meyer生命表分析显示，随访一年半时无事件生存率为86%，无tlr生存率为90%。结论：细胞捕获支架是安全有效的，具有令人满意的即时效果和中期结果，无支架血栓形成的证据。这些装置是否代表了目前可用的药物洗脱或裸金属支架的可行替代方案，需要在更大的随机研究中进行评估。(c) 2008 Wiley-Liss, Inc。
Objective: To prospectively evaluate the outcome with circulating endothelial progenitor cell (EPC) capture stent implantation in a cohort of consecutive patients with high-risk angiographic and/or clinical features. Background: Genous R-stent (TM) is a stainless steel coronary stent covered with antibodies specific to EPC's surface antigens, designed to promote the formation of a confluent functional endothelial layer over the device; conceivably, this may prevent both stent thrombosis and restenosis. Methods: From November 2005 to March 2007, 80 patients received 93 EPC capture stents at Campus Bio-Medico, University of Rome. Patients had two or more of the following high-risk features: diabetes mellitus (33%), unstable coronary syndromes (73%), left ventricular dysfunction (8%), multivessel intervention (9%), B2/C lesions (56%). Results: Acute success was achieved in 79/80 patients (98%), without Q-wave myocardial infarction (MI), in-hospital death or emergency bypass surgery; no patient had acute or subacute stent thrombosis. Follow-up was available in 78 patients (mean 14 +/- 4 months): noncardiac death occurred in one patient, acute MI in one patient; no patient required bypass surgery; 10 patients (13%) underwent percutaneous target lesion revascularization (TLR); three patients (4%) had reintervention on a nontarget vessel. Kaplan-Meyer life-table analysis showed event-free survival of 86% and TLR-free survival of 90% at one and a half year follow-up. Conclusions: The cell capture stent is safe and effective, with satisfactory immediate results and mid-term outcome, without evidence of stent thrombosis. Whether those devices represent a viable alternative to currently available drug-eluting or bare metal stents will need to be evaluated in larger randomized studies. (c) 2008 Wiley-Liss, Inc.